Sight Sciences wins broader TearCare label as dry eye revenue jumps 704%

Sight Sciences, Inc. (NASDAQ: SGHT) has gained an expanded U.S. Food and Drug Administration indication for its TearCare System that explicitly states the thermal-activated treatment improves meibomian gland function in adults with evaporative dry eye disease caused by meibomian gland dysfunction when used with manual gland expression. The updated indication became effective August 18 and gives Sight Sciences a more specific physiological claim than the device’s previous language around localized heat therapy and clearance of gland obstruction. The timing is commercially important because Sight Sciences’ Interventional Dry Eye revenue reached a record $2.7 million in the second quarter, up 704% from a year earlier and nearly double the first-quarter level. The company is therefore entering the second half of 2026 with both stronger reimbursement access and a regulatory label that more directly describes what physicians are trying to improve during treatment.

Sight Sciences describes TearCare as the first and only meibomian gland dysfunction treatment carrying an indication to improve meibomian gland function in dry-eye patients. That is a company characterization tied to the wording of the cleared indication rather than proof that TearCare is clinically superior to every alternative treatment. Even so, the revised label gives the commercial team a clearer evidence-based message at the same time as reimbursement is becoming less restrictive, potentially reducing two historical obstacles to adoption at once.

What changed in the FDA indication for TearCare?

TearCare uses wearable SmartLids components to deliver controlled heat to the eyelids while the patient can keep the eyes open and blink during treatment. The therapy is followed by manual expression of the meibomian glands, which are responsible for producing the lipid layer that helps prevent excessive tear evaporation. When the glands become obstructed or dysfunctional, patients can develop evaporative dry eye disease with symptoms including irritation, visual fluctuation, burning and discomfort.

The updated indication now states directly that TearCare is a thermal-activated gland-expression therapy that improves meibomian gland function in adult patients with evaporative dry eye disease due to meibomian gland dysfunction when used with manual expression. Sight Sciences also incorporated optional debridement into the treatment approach. The company argues that the revised wording better aligns the regulatory label with the physiological objective of treating gland dysfunction rather than only applying heat.

The treatment remains contraindicated in several circumstances, including recent eye or eyelid surgery, recent ocular injury and a history of certain ocular herpes infections. The expanded indication therefore broadens the clinical claim rather than changing TearCare into an unrestricted dry-eye intervention. Patient selection and physician judgment remain important.

Why does meibomian gland function matter commercially?

Dry eye is frequently treated with lubricating drops, anti-inflammatory medicines and other symptom-management approaches. Meibomian gland dysfunction targets a different part of the disease mechanism because inadequate or abnormal oil secretion can destabilize the tear film and accelerate evaporation. Sight Sciences has built TearCare around the argument that directly addressing obstructed glands should become an interventional treatment category in the same way that procedural therapies have gained traction in other ophthalmology markets.

The new label helps because reimbursement and physician adoption often depend not only on whether a device is cleared but also on how clearly its approved use maps onto a diagnosed disease mechanism. A claim that the therapy improves gland function is more specific than simply saying it delivers localized heat. That can support discussions with ophthalmologists, optometrists and payers seeking evidence that a procedure produces a measurable physiological benefit rather than temporary symptomatic relief.

What evidence supports the longer-term TearCare treatment effect?

Sight Sciences has highlighted results from the randomized SAHARA study, including a durability phase following patients for two years. Company materials report that clinical signs and symptoms remained statistically improved relative to baseline through 24 months and that 66% of participants who received TearCare at baseline and again around month five required no additional treatment under the study’s predefined retreatment criteria during the durability period. The company interprets those findings as evidence that periodic treatment can generate prolonged benefit for many patients.

Those data are useful for understanding treatment durability but should not be interpreted as meaning two procedures will produce two years of relief for every patient. Dry-eye severity, gland structure, underlying inflammatory disease and adherence to other therapies vary significantly. Commercial adoption will depend on whether physicians see reproducible outcomes across routine practice and whether reimbursement is sufficient to compensate providers for performing the procedure.

Why is TearCare revenue suddenly growing so quickly?

Sight Sciences reported second-quarter Interventional Dry Eye revenue of $2.7 million, up from only $300,000 in the comparable 2025 period and up 98% sequentially from $1.4 million in the first quarter. The company attributed the increase primarily to higher procedure volumes and higher average selling prices. The dry-eye segment remains far smaller than the $20.7 million Interventional Glaucoma business, but its growth is now fast enough to affect the company’s overall trajectory.

Reimbursement appears to be one of the main catalysts. Sight Sciences estimated that the number of patient lives with access to appropriate TearCare reimbursement increased from approximately 10.4 million to 14.5 million during the second quarter as additional insurer fee schedules reflected updated Medicare pricing for CPT code 0563T. Claims are still subject to individual medical-necessity determinations, so coverage figures should not be treated as guaranteed paid procedures. Even so, expanding access removes an important friction point for a treatment that historically faced substantial out-of-pocket limitations.

How important is TearCare to Sight Sciences’ overall financial recovery?

Sight Sciences generated second-quarter revenue of $23.4 million, up 20% year on year. Gross profit reached $21.4 million, while reported gross margin was 91%, including a tariff-refund benefit, and 86% excluding that benefit. Operating expenses fell 11% to $25.3 million, helping the net loss narrow 63% to $4.4 million from $11.9 million a year earlier. Cash and cash equivalents stood at $79.8 million against $40 million of long-term debt.

The stronger performance prompted Sight Sciences to raise full-year revenue guidance to $88 million to $92 million from $83 million to $89 million. Management now expects Interventional Dry Eye revenue of $9 million to $11 million compared with only $1.6 million in 2025, while glaucoma revenue is expected to reach $79 million to $81 million. That means TearCare is still the smaller business in absolute dollars but could account for a disproportionate share of incremental company growth.

A second meaningful development is improving unit economics. Interventional Dry Eye gross margin reached 85% in the quarter and approximately 80% excluding tariff refunds, up sharply from 38% a year earlier. Growing reimbursement and pricing therefore appear to be improving both revenue and profitability rather than simply generating additional low-margin procedures.

What does the TearCare indication mean for SGHT investor sentiment?

Sight Sciences shares closed at $8.26 on August 21, up 1.35% for the day. The stock had traded at $8.22 immediately before the expanded indication became public and reached $8.47 on August 19, indicating a positive but relatively measured market response rather than an abrupt speculative re-rating. The shares were also substantially above the roughly $4.91 level recorded one month earlier on July 21, reflecting broader optimism following strong second-quarter results, guidance changes and reimbursement developments.

The market response makes sense because the regulatory update strengthens an existing commercial product rather than creating an entirely new revenue stream overnight. The larger opportunity lies in combining label clarity, reimbursement access and a sales organization capable of converting coverage into recurring procedure volumes. If the dry-eye business reaches the upper end of management’s $9 million to $11 million 2026 forecast and continues scaling in 2027, TearCare could shift from an optional growth story into a meaningful second franchise alongside glaucoma.